A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Study Purpose
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 12 Years - 75 Years |
Gender | All |
Inclusion Criteria:
- - Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age.
- - Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria.
- - Active moderate to severe AD defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, body surface area (BSA) affected by AD ≥ 10%, and weekly average of daily Worst Pruritus numerical rating scale (NRS) score ≥ 4.
- - Candidate for systemic therapy or have recently required systemic therapy for AD.
- - Documented history (within 6 months prior to Baseline) of inadequate response to topical corticosteroid (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD or for whom topical treatments are otherwise medically inadvisable due to side effects or safety risks.
Exclusion Criteria:
- - Prior exposure to any Janus kinase (JAK) inhibitor.
- - Unable or unwilling to discontinue current AD treatments prior to the study.
- - Requirement of prohibited medications during the study.
- - Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03607422 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
AbbVie |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
ABBVIE INC. |
Principal Investigator Affiliation | AbbVie |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Active, not recruiting |
Countries | Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Atopic Dermatitis |
Study Website: | View Trial Website |
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, and a 30-day follow-up visit. Participants who meet eligibility criteria in the main study will be randomized in a 1:1:1 ratio to receive a daily oral dose of upadacitinib 30 mg or upadacitinib 15 mg or matching placebo. Upon completion of enrollment of a minimum of 810 participants in the main study, a supplemental study will continue to enroll adolescents (adolescent sub-study) until a total of 180 adolescent participants are enrolled overall (main study + adolescent sub-study). Randomization in the main study will be stratified by baseline disease severity (validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (United States [US]/Puerto Rico/Canada, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the adolescent sub-study will be stratified by baseline disease severity (moderate [vIGA-AD = 3] vs.#46; severe [vIGA-AD = 4]) and by geographic region (US/Puerto Rico/Canada and Other). At Week 16 of the main study and the adolescent sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period. In the main study the re-randomization at Week 16 will be stratified by Week 16 50% improvement in Eczema Area and Severity Index [EASI 50] responder [Yes/No], geographic region [US/Puerto Rico/Canada, and other], and age group [adolescent/adult]. For the adolescent sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other). Participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose. Starting at the Week 4 visit, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary. The Primary Analysis for the main study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the main study and the adolescent sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.
Arms
Placebo Comparator: Placebo / Upadacitinib
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
Experimental: Upadacitinib 15 mg QD
Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
Experimental: Upadacitinib 30 mg QD
Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
Interventions
Drug: - Placebo for Upadacitinib
Tablets taken orally once a day
Drug: - Upadacitinib
Tablets taken orally once a day
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Total Skin and Beauty Derm Ctr /ID# 205129
Birmingham, Alabama, 35205
Status
Address
Medical Dermatology Specialist /ID# 205516
Phoenix, Arizona, 85006-2722
Status
Address
Arizona Research Center, Inc. /ID# 205795
Phoenix, Arizona, 85053-4061
Status
Address
The Dermatology Clinic of Arkansas /ID# 218749
Bryant, Arkansas, 72022-7514
Status
Address
Arkansas Research Trials /ID# 218469
North Little Rock, Arkansas, 72117
Status
Address
Encino Research Center /ID# 207472
Encino, California, 91436
Status
Address
University of California Irvine /ID# 205136
Irvine, California, 92697-1385
Status
Address
Ark Clinical Research /ID# 218193
Long Beach, California, 90806-2325
Status
Address
Keck School of Medicine of USC /ID# 206971
Los Angeles, California, 90033
Status
Address
Wallace Medical Group /ID# 205701
Los Angeles, California, 90056
Status
Address
Child Hosp of Orange County,CA /ID# 205735
Orange, California, 92868
Status
Address
Palmtree Clinical Research Inc. /Id# 206184
Palm Springs, California, 92262
Status
Address
Rady Children's Hospital San Diego /ID# 208244
San Diego, California, 92123
Status
Address
Southern California Derma. Inc /ID# 205734
Santa Ana, California, 92701
Status
Address
Innovative Clinical Research - Lafayette /ID# 208400
Lafayette, Colorado, 80026
Status
Address
New England Research Associates, LLC /ID# 206896
Bridgeport, Connecticut, 06606-1827
Status
Address
Ideal Clinical Research Inc. /ID# 209880
Aventura, Florida, 33180
Status
Address
Skin Care Research, LLC /ID# 207099
Boca Raton, Florida, 33486-2269
Status
Address
Midflorida Clinical Research, Inc. /ID# 213700
Brandon, Florida, 33511-5335
Status
Address
Clinical Research of West Florida, Inc /ID# 206146
Clearwater, Florida, 33765
Status
Address
Revival Research /ID# 208383
Doral, Florida, 33122-1902
Status
Address
Universal Axon Clinical Research /ID# 213703
Doral, Florida, 33166
Status
Address
Savin Medical Group, LLC /ID# 206902
Miami Lakes, Florida, 33014-2490
Status
Address
Floridian Clinical Research /ID# 207433
Miami Lakes, Florida, 33016-1842
Status
Address
Lakes Research, LLC /ID# 209156
Miami, Florida, 33014
Status
Address
Miami Dade Medical Research Institute /ID# 209413
Miami, Florida, 33176
Status
Address
Advanced Research for Health Improvement /ID# 217987
Naples, Florida, 34102-5430
Status
Address
Advanced Research for Health Improvement /ID# 218003
Naples, Florida, 34102-5430
Status
Address
Complete Health Research /ID# 213459
Ormond Beach, Florida, 32174-6302
Status
Address
Precision Clinical Research /ID# 207364
Sunrise, Florida, 33351-7311
Status
Address
Clinical Research Trials of Florida, Inc. /ID# 206840
Tampa, Florida, 33607
Status
Address
ForCare Clinical Research /ID# 205120
Tampa, Florida, 33613-1244
Status
Address
Georgia Pollens Clinical Research Centers, Inc /ID# 218567
Albany, Georgia, 31707-1282
Status
Address
Marietta Dermatology Clinical Research /ID# 210317
Marietta, Georgia, 30060-1047
Status
Address
Agile Clinical Research Trials /ID# 218080
Sandy Springs, Georgia, 30342
Status
Address
Treasure Valley Medical Research /ID# 210298
Boise, Idaho, 83706
Status
Address
Great Lakes Clinical Trials /ID# 205830
Chicago, Illinois, 60640
Status
Address
Ashira Dermatology /ID# 205512
Gurnee, Illinois, 60031-3393
Status
Address
Clinical Investigation Specialists, Inc. /ID# 206898
Gurnee, Illinois, 60031
Status
Address
Northshore University Health System Dermatology Clinical Trials Unit /ID# 205135
Skokie, Illinois, 60077
Status
Address
Raga Clinical Studies, LLC. /ID# 206749
Crown Point, Indiana, 46307
Status
Address
Hutchinson Clinic /ID# 205970
Hutchinson, Kansas, 67502-1131
Status
Address
Continental Clinical Solutions /ID# 210327
Towson, Maryland, 21204
Status
Address
Beacon Clinical Research, LLC /ID# 206894
Quincy, Massachusetts, 02169
Status
Address
David Fivenson, MD, PLC /ID# 206903
Ann Arbor, Michigan, 48103
Status
Address
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 206895
Ann Arbor, Michigan, 48109
Status
Address
Allergy, Asthma & Immunology Associates, PC /ID# 218169
Lincoln, Nebraska, 68505-2343
Status
Address
Skin Specialists, PC /ID# 205515
Omaha, Nebraska, 68144
Status
Address
Duplicate_Summit Medical Group /ID# 213863
Clifton, New Jersey, 07012-1647
Status
Address
Skin Laser and Surgery Specialists of NY and NJ /ID# 206754
Hackensack, New Jersey, 07601-1997
Status
Address
Care Access Research /ID# 218476
Hoboken, New Jersey, 07030-2757
Status
Address
University of New Mexico School of Medicine /ID# 206756
Albuquerque, New Mexico, 87131-0001
Status
Address
Fordham Dermatology /ID# 218508
Bronx, New York, 10458-5046
Status
Address
PMG Research of Wilmington LLC /ID# 205968
Wilmington, North Carolina, 28401
Status
Address
University Hospitals Case Medical Center /ID# 206639
Cleveland, Ohio, 44106
Status
Address
Awasty Research Network, LLC /ID# 206748
Marion, Ohio, 43302-6225
Status
Address
Southside Dermatology /ID# 214451
Tulsa, Oklahoma, 74132
Status
Address
Vital Prospects Clinical Research Institute, PC /ID# 205824
Tulsa, Oklahoma, 74136-7049
Status
Address
Cyn3rgy Research /ID# 218064
Gresham, Oregon, 97030-8316
Status
Address
Velocity Clinical Research Hallandale Beach /ID# 207544
Medford, Oregon, 97504
Status
Address
Clinical Research Solutions, LLC /ID# 218416
Jackson, Tennessee, 38305-2163
Status
Address
Stones River Dermatology /ID# 205178
Murfreesboro, Tennessee, 37129-3194
Status
Address
Metroplex Dermatology /ID# 213307
Arlington, Texas, 76014-3105
Status
Address
Bellaire Dermatology /ID# 205470
Bellaire, Texas, 77401
Status
Address
Center for Clinical Studies /ID# 213186
Cypress, Texas, 77433
Status
Address
Dermatology Treatment and Research Center, PA /ID# 205473
Dallas, Texas, 75230
Status
Address
Epiphany Dermatology - Fort Worth /ID# 210073
Fort Worth, Texas, 76244-6548
Status
Address
Styde Research, LLC /ID# 213469
Lewisville, Texas, 75067
Status
Address
Austin Institute for Clinical Research /ID# 206640
Pflugerville, Texas, 78660
Status
Address
Derm Clin Res Ctr San Antonio /ID# 205469
San Antonio, Texas, 78229
Status
Address
EPIC Medical Research /ID# 206382
Murray, Utah, 84123-5632
Status
Address
Aspen Clinical Research /ID# 208399
Orem, Utah, 84058
Status
Address
Timber Lane Allergy & Asthma Research, LLC /ID# 206897
South Burlington, Vermont, 05403-7204
Status
Address
The Education & Research Foundation, Inc. /ID# 206900
Lynchburg, Virginia, 24501-1403
Status
Address
Bellingham Asthma Allergy and Immunology Clinic /ID# 210357
Bellingham, Washington, 98225-1945
Status
Address
Clinical Investigation Specialist, Inc - Kenosha /ID# 215933
Kenosha, Wisconsin, 53144-1782
International Sites
Status
Address
The Skin Hospital /ID# 217846
Westmead, New South Wales, 2145
Status
Address
The Skin Centre /ID# 205922
Benowa, Queensland, 4217
Status
Address
Box Hill Hospital /ID# 206023
Box Hill, Victoria, 3128
Status
Address
Monash Children's Hospital /ID# 217917
Clayton, Victoria, 3168
Status
Address
Sinclair Dermatology /ID# 217791
East Melbourne, Victoria, 3002
Status
Address
The Royal Melbourne Hospital /ID# 205919
Parkville, Victoria, 3050
Status
Address
Murdoch Children's Research Institute /ID# 205667
Parkville, Victoria, 3052
Status
Address
Universitaetsklinikum St. Poelten /ID# 206909
Sankt Poelten, Niederoesterreich, 3100
Status
Address
Ordensklinikum Linz GmbH Elisabethinen /ID# 206573
Linz, Oberoesterreich, 4010
Status
Address
Klinik Donaustadt /ID# 206572
Vienna, Wien, 1220
Status
Address
Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 208281
Salzburg, , 5020
Status
Address
UCL Saint-Luc /ID# 205537
Woluwe-Saint-Lambert, Bruxelles-Capitale, 1200
Status
Address
UZ Gent /ID# 205181
Gent, Oost-Vlaanderen, 9000
Status
Address
Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 204938
Liege, , 4000
Status
Address
Medical center Sveti Panteleimon /ID# 210414
Sofia, , 1000
Status
Address
Acibadem City Clinic Tokuda University Hospital EAD /ID# 205292
Sofia, , 1407
Status
Address
Military Medical Academy Multiprofile Hospital /ID# 205291
Sofia, , 1606
Status
Address
Medical complex Doverie /ID# 211289
Sofia, , 1632
Status
Address
Stratica Medical /ID# 205415
Edmonton, Alberta, T5K 1X3
Status
Address
Alberta DermaSurgery Centre /ID# 205422
Edmonton, Alberta, T6G 1C3
Status
Address
UBC Department of Dermatology and Skin Science The Skin Care Centre /ID# 207837
Vancouver, British Columbia, V5Z 4E8
Status
Address
Pacific Derm /ID# 206797
Vancouver, British Columbia, V6H 4E1
Status
Address
Skin Care Studio /ID# 205420
St. John's, Newfoundland and Labrador, A1E 1V4
Status
Address
SimcoDerm Medical and Surgical Dermatology Center /ID# 206333
Barrie, Ontario, L4M 7G1
Status
Address
Kingsway Clinical Research /ID# 206005
Etobicoke, Ontario, M8X 1Y9
Status
Address
Dr. Dusan Sajic Medicine Professional Corporation /ID# 206890
Guelph, Ontario, N1L 0B7
Status
Address
The Guenther Dermatology Research Centre /ID# 206772
London, Ontario, N6A 3H7
Status
Address
DermEdge Research Inc. /ID# 206036
Mississauga, Ontario, L5H 1G9
Status
Address
Dr. S.K. Siddha Medicine Professional Corporation /ID# 207138
Newmarket, Ontario, L3Y 5G8
Status
Address
Allergy Research Canada Inc. /ID# 213547
Niagara Falls, Ontario, L2H 1H5
Status
Address
Dr. Lyne Giroux Medicine Professional Corporation /ID# 206771
Sudbury, Ontario, P3C 1X8
Status
Address
Niakosari Medicine Professional Corporation /ID# 206004
Toronto, Ontario, M2M 4J5
Status
Address
Skinsense Medical Research /ID# 206873
Saskatoon, Saskatchewan, S7K 0H6
Status
Address
DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 205429
Zagreb, Grad Zagreb, 10000
Status
Address
Djecja bolnica Srebrnjak /ID# 205926
Zagreb, Grad Zagreb, 10000
Status
Address
Poliklinika Vlatka Cavka d.o.o. /ID# 211126
Zagreb, Grad Zagreb, 10000
Status
Address
Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 203448
Ivanic-Grad, Zagrebacka Zupanija, 10310
Status
Address
Fakultni nemocnice Plzen /ID# 205096
Plzen, , 305 99
Status
Address
Sanatorium profesora Arenbergera /ID# 205098
Praha, , 110 00
Status
Address
Vseobecna fakultni nemocnice v Praze /ID# 205201
Praha, , 128 08
Status
Address
Fakultni Nemocnice v Motole /ID# 218192
Praha, , 150 06
Status
Address
Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o. z. /ID# 205097
Usti nad Labem, , 400 11
Status
Address
Aarhus University Hospital /ID# 205524
Aarhus N, Midtjylland, 8200
Status
Address
Sjællands Universitetshospital /ID# 205960
Roskilde, Sjælland, 4000
Status
Address
Hopital Prive d'Antony /ID# 206553
Antony, Ile-de-France, 92160
Status
Address
Hopital Saint-Andre /ID# 206554
Bordeaux, , 33075
Status
Address
CHRU de Brest - Hopital Morvan /ID# 206555
Brest, , 29200
Status
Address
C.H. de Bretagne Sud /ID# 206910
Lorient, , 56322
Status
Address
AP-HP - Hopital Saint-Louis /ID# 206552
Paris, , 75010
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 206658
Kiel, Schleswig-Holstein, 24105
Status
Address
Klinikum Darmstadt /ID# 207483
Darmstadt, , 64283
Status
Address
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 205767
Dresden, , 01307
Status
Address
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207982
Hamburg, , 20246
Status
Address
Dermatologische Gemeinschaftspraxis Mahlow /ID# 205765
Mahlow, , 15831
Status
Address
Haut- und Laserzentrum Hunsrück /ID# 205768
Simmern, , 55469
Status
Address
Hautarztpraxis Dr. med. Matthias Hoffmann /ID# 205766
Witten, , 58453
Status
Address
CentroDerm GmbH /ID# 206861
Wuppertal, , 42287
Status
Address
251 Airforce General Hospital /ID# 205841
Athens, Attiki, 11525
Status
Address
401 GSNA - 401 Army General Hospital /ID# 205352
Athens, Attiki, 11525
Status
Address
General Hospital Andreas Syggros /ID# 204527
Athens, Attiki, 16121
Status
Address
Papageorgiou General Hospital Thessaloniki /ID# 204526
Stavroupoli (Thessalonikis), Thessaloniki, 55536
Status
Address
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 218072
Miskolc, Borsod-Abauj-Zemplen, 3526
Status
Address
Bugat Pal Korhaz /ID# 211247
Gyöngyös, Heves, 3200
Status
Address
Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 205611
Kaposvár, Somogy, 7400
Status
Address
Drug Research Center /ID# 217855
Balatonfured, Veszprem, 8230
Status
Address
Clinexpert Kft /ID# 211246
Budapest, , 1033
Status
Address
Synexus Magyarorszag Kft. /ID# 206008
Budapest, , 1036
Status
Address
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 205085
Pecs, , 7624
Status
Address
St James Hospital /ID# 204264
Dublin 8, Dublin, D08 NHY1
Status
Address
South Infirmary Victoria University Hospital /ID# 204265
Cork, , T12 X23H
Status
Address
University Hospital Galway /ID# 209965
Galway, , H91 YR71
Status
Address
University Hospital Waterford /ID# 204266
Waterford, , X91 ER8E
Status
Address
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 205986
Rome, Lazio, 00144
Status
Address
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 205987
Rome, Lazio, 00168
Status
Address
ASST Spedali civili di Brescia /ID# 205927
Brescia, , 25123
Status
Address
Azienda Ospedaliero Universitaria di Cagliari- Presidio Ospedaliero /ID# 205168
Cagliari, , 09124
Status
Address
Presidio Ospedaliero San Salvatore /ID# 205167
L'Aquila, , 67100
Status
Address
Azienda Ospedaliero-Universitaria di Modena /ID# 205169
Modena, , 41124
Status
Address
Korea University Ansan Hospital /ID# 206342
Ansan, Gyeonggido, 15355
Status
Address
SoonChunHyang University Buchon Hospital /ID# 206391
Buncheon, Gyeonggido, 14584
Status
Address
Ajou University Hospital /ID# 206341
Suwon, Gyeonggido, 16499
Status
Address
The Catholic University of Korea Incheon St.Mary's Hospital /ID# 206529
Incheon, , 21431
Status
Address
Seoul National University Hospital /ID# 206396
Seoul, , 03080
Status
Address
Chung-Ang University Hostipal /ID# 206397
Seoul, , 06973
Status
Address
Hallym University Kangnam Sacred Heart Hospital /ID# 206343
Seoul, , 07441
Status
Address
Bravis Ziekenhuis /ID# 206676
Bergen op Zoom, Noord-Brabant, 4624 VT
Status
Address
Centrum Oosterwal /ID# 209640
Alkmaar, , 1817 MS
Status
Address
Reinier de Graaf /ID# 205811
Delft, , 2625 AD
Status
Address
Universitair Medisch Centrum Groningen /ID# 205162
Groningen, , 9713 GZ
Status
Address
Greenlane Clinical Centre /ID# 205664
Epsom, Auckland, 1051
Status
Address
CCA Braga - Hospital de Braga /ID# 205854
Braga, , 4710-243
Status
Address
Centro Hospitalar de Leiria, EPE /ID# 209906
Leiria, , 2410-197
Status
Address
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 205839
Lisboa, , 1649-035
Status
Address
Hospital CUF Descobertas /ID# 205431
Lisboa, , 1998-018
Status
Address
CHP, EPE- Hospital Geral de Sa /ID# 205187
Porto, , 4050
Status
Address
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 205679
Porto, , 4200-319
Status
Address
National Skin Centre /ID# 205222
Singapore, Central Singapore, 308205
Status
Address
National University Hospital /ID# 205224
Singapore, , 119074
Status
Address
Singapore General Hospital /ID# 205225
Singapore, , 169608
Status
Address
KK Women's & Children Hospital /ID# 206693
Singapore, , 229899
Status
Address
Changi General Hospital /ID# 205223
Singapore, , 529889
Status
Address
Hospital Vital Alvarez Buylla /ID# 205770
Mieres, Asturias, 33611
Status
Address
Hospital Sant Joan de Deu /ID# 218047
Esplugues de Llobregat, Barcelona, 08950
Status
Address
Hospital Parc de Salut del Mar /ID# 204709
Barcelona, , 08003
Status
Address
Hospital Clinic de Barcelona /ID# 210564
Barcelona, , 08036
Status
Address
Hospital Universitario Reina Sofia /ID# 204712
Cordoba, , 14004
Status
Address
Hospital Campus de la Salud /ID# 205544
Granada, , 18016
Status
Address
Hospital General Universitario Gregorio Maranon /ID# 204380
Madrid, , 28007
Status
Address
Hospital Infantil Universitario Nino Jesus /ID# 210437
Madrid, , 28009
Status
Address
Hospital Universitario Infanta Leonor /ID# 204710
Madrid, , 28031
Status
Address
Hospital General Universitario de Valencia /ID# 210565
Valencia, , 46014
Status
Address
Taipei Medical University Shuang Ho Hospital /ID# 204804
New Taipei City, , 23561
Status
Address
Chung Shan Medical University Hospital /ID# 205092
Taichung, , 40201
Status
Address
National Taiwan University Hospital /ID# 204803
Taipei City, , 100
Status
Address
Linkou Chang Gung Memorial Ho /ID# 204783
Taoyuan City, , 333
Status
Address
University Hospital Southampton NHS Foundation Trust /ID# 205711
Southampton, Hampshire, SO16 6YD
Status
Address
Northwick Park Hospital /ID# 205250
Middlesex, Harrow, HA1 3UJ
Status
Address
Barts Health NHS Trust /ID# 206491
London, London, City Of, E1 2ES
Status
Address
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 204993
Newcastle Upon Tyne, , NE7 7DN
Status
Address
University Hospital Plymouth NHS Trust /ID# 204649
Plymouth, , PL6 8DH